Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (967)	5/8/2006 2:09:57 PM
From: Mike McFarland	Respond to of 1336

INFI ARQL finance.messages.yahoo.com This market cap is equivalent to that of ARQL except that in a share of ARQL one gets about $4/share in cash and the business for the balance i.e about $2.30/share ( the proportions are 2/1 in favour of cash/share). This,IMHO, makes ARQL a less expensive stock... Arqule At March 31, 2006, the Company had a total of approximately $131,512,000 in cash and marketable securities. ArQule Maintains Financial Guidance As previously announced, ArQule plans to exit the chemistry services business upon conclusion of the Pfizer agreement in May, 2006. As a result, it is anticipated that the revenue and associated costs related to the chemistry services business will be reported as discontinued operations in the second quarter of 2006. Of the $23.5 million in revenue reported this quarter, approximately $21 million is likely to be presented next quarter as discontinued operations. Consequently, the Company is reiterating its 2006 financial guidance, which remains unchanged. For 2006, as previously announced, ArQule expects total revenues from ongoing operations for the year to range between $6.5 and $7 million, primarily related to the partnership with Roche. Net use of cash is expected to range between $53 and $59 million. Net loss is expected to range between $33 and $39 million, and net loss per share is expected to range between $0.93 and $1.10 for the year. ArQule expects to end 2006 with between $82 and $88 million in cash and marketable securities. finance.yahoo.com In a six month race, and for the the five years chart, the two stocks match up. The two year chart shows that Arqule happened to far outperform for that particular time period. Fun and games. What I want to know is what the INFI ARQL five year chart looks like in 2011. I wouldn't be surprised to find that Graben4 works for a biotech mutual fund or a hedge fund. A bit arrogant--but seems to be on the money. I also like to read posts by microcapfun: search.messages.yahoo.com Finally, there is a fairly juvenile and transparent attempt at bashing HSP90 on the Yahoo DPII thread of late. Looks like some daytraders are trying to buy a few shares or something.